Equibles does not estimate personal net worth.
Carl Hull was last confirmed as CEO at Maravai Lifesciences Holdings, Inc. (MRVI) in a filing dated April 20, 2023. Earlier roles on record: Chairman and Board Member at Maravai Lifesciences Holdings, Inc. (MRVI) until December 5, 2024. Maravai Lifesciences Holdings, Inc. reported in an 8-K filed December 5, 2024 that Carl Hull resigned as member of the Board of Directors, effective December 5, 2024. Maravai Lifesciences Holdings, Inc. reported in an 8-K filed December 5, 2024 that Carl Hull retired as Executive Chairman of the Board, effective December 5, 2024. Maravai Lifesciences Holdings, Inc. reported in an 8-K filed October 19, 2022 that Carl Hull was appointed interim Chief Executive Officer, effective October 18, 2022. The proxy statement of Maravai Lifesciences Holdings, Inc. reports total compensation of $5,217,013 for Carl Hull in fiscal 2023, including a base salary of $617,668. Disclosed compensation is on record for 5 fiscal years. Carl Hull has spoken on 11 earnings calls across 1 company, most recently for Maravai Lifesciences Holdings, Inc. on August 7, 2023. The companies whose calls Carl Hull spoke on are classified in the Healthcare sector.
“On December 3, 2024, Carl Hull, Executive Chairman of the Board of Directors (the "Board") of Maravai LifeSciences Holdings, Inc. (the "Company"), notified the Board of his decision to retire as Executive Chairman and to resign from the Board, both effective as of December 5, 2024.”
“On December 3, 2024, Carl Hull, Executive Chairman of the Board of Directors (the "Board") of Maravai LifeSciences Holdings, Inc. (the "Company"), notified the Board of his decision to retire as Executive Chairman and to resign from the Board, both effective as of December 5, 2024.”
“Well, thank you, Deb, and good afternoon, everyone. We appreciate having you join us for our call today. During this call, we will provide the details of our financial results for the last quarter and our updated guidance.”
“Well, thank you, Deb, and good afternoon, everyone. We appreciate having you join us for our call today. Let me give a quick recap of the quarter and highlight some innovative new products that we are introducing and provide a few business updates before turning the call over to Kevin.”
“Well, thank you, Deb, and good afternoon, everyone. We appreciate having you join us for our call today. Let's start with our fourth quarter results on Slide 5.”
“Well, thank you, Deb, and good afternoon, everyone. We appreciate having you join us for our call today. Let me now give you a quick recap of the quarter and provide a few business updates before turning the call over to Kevin.”
“Well, thank you, Deb, and good afternoon, everyone. We appreciate you joining us for our call today. Let me start with the fact that we had a great quarter. Our strong second quarter results completed a record first half of the year.”
2020-01-01–2024-12-05
Start not stated–2023-04-20
Last confirmed by a filing; no departure on record
Start not stated–2024-12-05
Biotechnology · Healthcare
CEO, Chairman, Board Member
2020-01-01–2024-12-05
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Maravai Lifesciences Holdings, Inc. (MRVI) | Executive Chairman and Former Interim Chief Executive Officer | $617,668 | $5,217,013 |
| 2022 | Maravai Lifesciences Holdings, Inc. (MRVI) | Executive Chairman and Former Interim Chief Executive Officer | $721,383 | $5,480,801 |
| 2021 | Maravai Lifesciences Holdings, Inc. (MRVI) | Executive Chairman and Former Interim Chief Executive Officer | $580,769 | $1,780,769 |
| 2020 | Maravai Lifesciences Holdings, Inc. (MRVI) | Chief Executive Officer | $500,000 | $2,124,160 |
| 2019 | Maravai Lifesciences Holdings, Inc. (MRVI) | Chief Executive Officer | $485,417 | $2,828,417 |
